CVKD logo

CADRENAL THERAPEUTICS INC

CVKDNASDAQ
🏆 #5233 by market capUS Equity
$1.09▼ $0.01 (−0.91%)
Live
🔔
Track CVKD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d▼ 2.2%
14d▼ 0.5%
30d▼ 28.8%
ytd▼ 83.8%
1y▼ 92.1%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
60
Fair

Trading Snapshot

Day Range
$1.07 – $1.10
52-Week Range
$1.00 – $14.64
Volume
$3.76B
Avg Volume
$3.88B
Shares Outstanding
3.1M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$278,716
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-4.92
Dividend Yield
—
Dilution (1yr)
+30.7%

Why Investors Own CVKD

  • ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 70% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CVKD logo

CADRENAL THERAPEUTICS INC

CVKD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +22.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +71.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.0M▲ +30.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$6M YoY
StockOtter · stockotter.space

About CADRENAL THERAPEUTICS INC

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1.42
▲ +29.9% Upside
High Target$1.69
Low Target$1.27
Based on 24 analysts

Latest News & Updates

🚀
Barron’s·2h ago

CADRENAL THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift CVKD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

CADRENAL THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.